These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 38514482)

  • 1. State of the Art of Silica Nanoparticles: An Overview on Biodistribution and Preclinical Toxicity Studies.
    Yu J; Dan N; Eslami SM; Lu X
    AAPS J; 2024 Mar; 26(3):35. PubMed ID: 38514482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosafety of mesoporous silica nanoparticles; towards clinical translation.
    Lérida-Viso A; Estepa-Fernández A; García-Fernández A; Martí-Centelles V; Martínez-Máñez R
    Adv Drug Deliv Rev; 2023 Oct; 201():115049. PubMed ID: 37573951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution, excretion, and toxicity of mesoporous silica nanoparticles after oral administration depend on their shape.
    Li L; Liu T; Fu C; Tan L; Meng X; Liu H
    Nanomedicine; 2015 Nov; 11(8):1915-24. PubMed ID: 26238077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to Regulate the Degradation and Clearance of Mesoporous Silica Nanoparticles: A Review.
    Zhang Y; Lin X; Chen X; Fang W; Yu K; Gu W; Wei Y; Zheng H; Piao J; Li F
    Int J Nanomedicine; 2024; 19():5859-5878. PubMed ID: 38887691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on percutaneous penetration: Silica nanoparticles.
    Nafisi S; Schäfer-Korting M; Maibach HI
    Nanotoxicology; 2015; 9(5):643-57. PubMed ID: 25286334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage.
    Rosenholm JM; Mamaeva V; Sahlgren C; Lindén M
    Nanomedicine (Lond); 2012 Jan; 7(1):111-20. PubMed ID: 22191780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution and Excretion of Intravenously Injected Mesoporous Silica Nanoparticles: Implications for Drug Delivery Efficiency and Safety.
    Lindén M
    Enzymes; 2018; 43():155-180. PubMed ID: 30244806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Senescence and the Impact on Biodistribution of Different Nanosystems: the Discrepancy on Tissue Deposition of Graphene Quantum Dots, Polycaprolactone Nanoparticle and Magnetic Mesoporous Silica Nanoparticles in Young and Elder Animals.
    Dos Reis SRR; Pinto SR; de Menezes FD; Martinez-Manez R; Ricci-Junior E; Alencar LMR; Helal-Neto E; da Silva de Barros AO; Lisboa PC; Santos-Oliveira R
    Pharm Res; 2020 Jan; 37(3):40. PubMed ID: 31970499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesoporous silica nanoparticles: facile surface functionalization and versatile biomedical applications in oncology.
    Huang R; Shen YW; Guan YY; Jiang YX; Wu Y; Rahman K; Zhang LJ; Liu HJ; Luan X
    Acta Biomater; 2020 Oct; 116():1-15. PubMed ID: 32911102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer.
    Li T; Shi S; Goel S; Shen X; Xie X; Chen Z; Zhang H; Li S; Qin X; Yang H; Wu C; Liu Y
    Acta Biomater; 2019 Apr; 89():1-13. PubMed ID: 30797106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silica nanoparticles: preparation, characterization and in vitro/in vivo biodistribution studies.
    Tamba BI; Dondas A; Leon M; Neagu AN; Dodi G; Stefanescu C; Tijani A
    Eur J Pharm Sci; 2015 Apr; 71():46-55. PubMed ID: 25681629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesoporous silica nanoparticles in nanomedicine applications.
    Manzano M; Vallet-Regí M
    J Mater Sci Mater Med; 2018 May; 29(5):65. PubMed ID: 29737405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesoporous silica nanoparticles in drug delivery and biomedical applications.
    Wang Y; Zhao Q; Han N; Bai L; Li J; Liu J; Che E; Hu L; Zhang Q; Jiang T; Wang S
    Nanomedicine; 2015 Feb; 11(2):313-27. PubMed ID: 25461284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery.
    Li Z; Zhang Y; Feng N
    Expert Opin Drug Deliv; 2019 Mar; 16(3):219-237. PubMed ID: 30686075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silica-Based Nanoparticles for Biomedical Applications: From Nanocarriers to Biomodulators.
    Yang Y; Zhang M; Song H; Yu C
    Acc Chem Res; 2020 Aug; 53(8):1545-1556. PubMed ID: 32667182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subchronic toxicity of silica nanoparticles as a function of size and porosity.
    Mohammadpour R; Yazdimamaghani M; Cheney DL; Jedrzkiewicz J; Ghandehari H
    J Control Release; 2019 Jun; 304():216-232. PubMed ID: 31047961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of biomimetically synthesized mesoporous silica nanoparticles as drug carriers: Structure, wettability, degradation, biocompatibility and brain distribution.
    Li H; Wu X; Yang B; Li J; Xu L; Liu H; Li S; Xu J; Yang M; Wei M
    Mater Sci Eng C Mater Biol Appl; 2019 Jan; 94():453-464. PubMed ID: 30423730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis.
    Gupta A; Kushwaha SS; Mishra A
    Recent Pat Drug Deliv Formul; 2020; 14(2):126-144. PubMed ID: 32928094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery.
    Kolimi P; Narala S; Youssef AAA; Nyavanandi D; Dudhipala N
    Nanotheranostics; 2023; 7(1):70-89. PubMed ID: 36593800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theragnostic potentials of core/shell mesoporous silica nanostructures.
    Ravindran Girija A; Balasubramanian S
    Nanotheranostics; 2019; 3(1):1-40. PubMed ID: 30662821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.